阿尔茨海默病与骨质疏松症相关性研究进展

doi:10.3969/j.issn.1003-9198.2025.09.016

摘要/Abstract

摘要： 随着全球老龄化进程加速,AD和骨质疏松症(OP)的发病率逐年上升,二者对老年人的生活品质及健康寿命造成了重大影响。近年来,越来越多的研究聚焦于AD与OP之间的相关性,探索其共有的风险,包括炎症反应、维生素D缺乏、激素失衡以及遗传因素等方面。流行病学研究显示两者常相伴发生,且在疾病进展过程中相互影响。本文就其共同生理病理、流行病学、相互影响的机制方面的研究进展进行综述,深入了解AD与OP的关联,有望为早期诊断、预防及综合治疗提供新的思路和策略,从而改善病人预后,减轻家庭与社会负担。

关键词: 阿尔茨海默病, 骨质疏松症, 流行病学, 关联机制

Abstract: With the acceleration of the global aging, the incidences of Alzheimer’s disease (AD) and osteoporosis (OP) are increasing year by year, and they both seriously affect the quality of life and healthspan of the elderly. In recent years, more and more studies have focused on the correlation between AD and OP, exploring their common risks, including inflammatory responses, vitamin D deficiency, hormonal imbalances, and genetic factors. Epidemiological studies have shown that the two diseases often occur concomitantly and affect each other. This review summarizes the research progress on their common physiological and pathological aspects, epidemiology, and the mechanisms of mutual influence. A deep understanding of the association between AD and OP is expected to provide new ideas and strategies for early diagnosis, prevention, and comprehensive treatment, ultimately improving the prognosis of patients and reducing the burden on families and society.

Key words: Alzheimer’s disease, osteoporosis, epidemiology, correlation mechanism

中图分类号:

王淼慧, 樊旭航, 陈思瑶, 杨晓娟. 阿尔茨海默病与骨质疏松症相关性研究进展[J]. 实用老年医学, 2025, 39(9): 937-941.

WANG Miaohui, FAN Xuhang, CHEN Siyao, YANG Xiaojuan. Research progress on the correlation between Alzheimer’s disease and osteoporosis[J]. Practical Geriatrics, 2025, 39(9): 937-941.

参考文献

[1] 王刚, 齐金蕾, 刘馨雅, 等.中国阿尔茨海默病报告2024[J]. 诊断学理论与实践, 2024, 23(3): 219-256.
[2] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022)[J]. 中国全科医学, 2023, 26(14): 1671-1691.
[3] TANG A S, RANKIN K P, CERONO G, et al. Leveraging electronic health records and knowledge networks for Alzheimer’s disease prediction and sex-specific biological insights[J]. Nat Aging, 2024, 4(3): 379-395.
[4] 叶秋燕, 李雪, 高伟, 等. 基于“脑-骨轴”探讨阿尔茨海默病与骨质疏松症的相关性[J/OL]. (2024-09-03). 中医学报, 1-8. http://kns.cnki.net/kcms/detail/41.1411.R.20240903.0922.010.html.
[5] ZHANG F, ZHANG W. Research progress in Alzheimer’s disease and bone-brain axis[J]. Ageing Res Rev, 2024, 98: 102341.
[6] KERSCHAN-SCHINDL K. Prevention and rehabilitation of osteoporosis[J].Wien Med Wochenschr, 2016, 166(1/2): 22-27.
[7] XIAO T, GHATAN S, MOOLDIJK S S, et al. Association of bone mineral density and dementia: the Rotterdam study[J]. Neurology, 2023, 100(20): e2125-e2133.
[8] KOSTEV K, HADJI P, JACOB L. Impact of osteoporosis on the risk of dementia in almost 60, 000 patients followed in general practices in Germany[J]. J Alzheimers Dis, 2018, 65(2): 401-407.
[9] LIN S F, FAN Y C, PAN W H, et al. Bone and lean mass loss and cognitive impairment for healthy elder adults: analysis of the nutrition and health survey in Taiwan 2013-2016 and a validation study with structural equation modeling[J]. Front Nutr, 2021, 8: 747877.
[10] LOSKUTOVA N, HONEA R A, VIDONI E D, et al. Bone density and brain atrophy in early Alzheimer’s disease[J]. J Alzheimers Dis, 2009, 18(4): 777-785.
[11] XIONG J, KANG S S, WANG Z, et al. FSH blockade improves cognition in mice with Alzheimer’s disease[J]. Nature, 2022, 603(7901): 470-476.
[12] GILLESPIE C W, MORIN P E. Trends and disparities in osteoporosis screening among women in the United States, 2008-2014[J]. Am J Med, 2017, 130(3): 306-316.
[13] LU L, TIAN L. Postmenopausal osteoporosis coexisting with sarcopenia: the role and mechanisms of estrogen[J]. J Endocrinol, 2023, 259(1): e230116.
[14] DUONG T, NIKOLAEVA M, ACTON P J. C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer’s disease[J]. Brain Res, 1997, 749(1): 152-156.
[15] MCGEER E G, MCGEER P L. Neuroinflammation in Alzheimer’s disease and mild cognitive impairment: a field in its infancy[J]. J Alzheimers Dis, 2010, 19(1): 355-361.
[16] FISCHER V, HAFFNER-LUNTZER M. Interaction between bone and immune cells:implications for postmenopausal osteoporosis[J]. Semin Cell Dev Biol, 2022, 123: 14-21.
[17] 刘雅利, 封俨宸, 党雪, 等. 免疫细胞介导的炎症与骨质疏松症的机制与作用途径[J]. 中国骨质疏松杂志, 2024, 30(6): 863-868.
[18] SULTAN S, TAIMURI U, BASNAN S A, et al. Low vitamin D and its association with cognitive impairment and dementia[J]. J Aging Res, 2020, 2020: 6097820.
[19] ANNWEILER C, LLEWELLYN D J, BEAUCHET O. Low serum vitamin D concentrations in Alzheimer’s disease: a systematic review and meta-analysis[J]. J Alzheimers Dis, 2013, 33(3): 659-674.
[20] LITTLEJOHNS T J, HENLEY W E, LANG I A, et al. Vitamin D and the risk of dementia and Alzheimer disease[J]. Neurology, 2014, 83(10): 920-928.
[21] ANNWEILER C. Vitamin D in dementia prevention[J]. Ann N Y Acad Sci, 2016, 1367(1): 57-63.
[22] GOLTZMAN D. Functions of vitamin D in bone[J]. Histochem Cell Biol, 2018, 149(4): 305-312.
[23] ZHANG Y, CHEN C Y, LIU Y W, et al. Neuronal induction of bone-fat imbalance through osteocyte neuropeptide Y[J]. Adv Sci: Weinh, 2021, 8(24): e2100808.
[24] LIU X, CHEN C, JIANG Y, et al. Brain-derived extracellular vesicles promote bone-fat imbalance in Alzheimer’s disease[J]. Int J Biol Sci, 2023, 19(8): 2409-2427.
[25] LI S, LIU B, ZHANG L, et al. Amyloid beta peptide is elevated in osteoporotic bone tissues and enhances osteoclast function[J]. Bone, 2014, 61: 164-175.
[26] LI S, YANG B, TEGUH D, et al. Amyloid β peptide enhances RANKL-induced osteoclast activation through NF-κB, ERK, and calcium oscillation signaling[J]. Int J Mol Sci, 2016, 17(10): 1683.
[27] DENGLER-CRISH C M, SMITH M A, WILSON G N. Early evidence of low bone density and decreased serotonergic synthesis in the dorsal raphe of a tauopathy model of Alzheimer’s disease[J]. J Alzheimers Dis, 2017, 55(4): 1605-1619.
[28] CHEN M, FU W, XU H, et al. Tau deficiency inhibits classically activated macrophage polarization and protects against collagen-induced arthritis in mice[J]. Arthritis Res Ther, 2023, 25(1): 146.
[29] FORTEA J, PEGUEROLES J, ALCOLEA D, et al. Publisher correction: APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease[J].Nat Med, 2024, 30(7): 2093.
[30] RAULIN A C, DOSS S V, TROTTIER Z A, et al. ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies[J]. Mol Neurodegener, 2022, 17(1): 72.
[31] 孙金磊. APOE基因多态性与骨质疏松性骨折易感性关系的研究[D]. 济南: 山东大学, 2018.
[32] ASCONE G, DI CEGLIE I, WALGREEN B, et al. High LDL levels lessen bone destruction during antigen-induced arthritis by inhibiting osteoclast formation and function[J]. Bone, 2020, 130: 115140.
[33] DOWNEY C L, YOUNG A, BURTON E F, et al. Dementia and osteoporosis in a geriatric population:is there a common link?[J]. World J Orthop, 2017, 8(5): 412-423.
[34] LIU C C, TSAI C W, DEAK F, et al. Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer’s disease[J]. Neuron, 2014, 84(1): 63-77.
[35] PALOMER E, BUECHLER J, SALINAS P C. Wnt signaling deregulation in the aging and Alzheimer’s brain[J]. Front Cell Neurosci, 2019, 13: 227.
[36] SHI T, SHEN S, SHI Y, et al. Osteocyte-derived sclerostin impairs cognitive function during ageing and Alzheimer’s disease progression[J]. Nat Metab, 2024, 6(3): 531-549.
[37] KARSENTY G, OLSON E N. Bone and muscle endocrine functions: unexpected paradigms of inter-organ communication[J]. Cell, 2016, 164(6): 1248-1256.
[38] KUMAR S, CHANDNANI A, AUNG N H, et al. Alzheimer’s disease and its association with bone health: a case-control study[J]. Cureus, 2021, 13(3): e13772.
[39] PU Z, TANG X, FEI Y E, et al. Bone metabolic biomarkers and bone mineral density in male patients with early-stage Alzheimer’s disease[J]. Eur Geriatr Med, 2020, 11(3): 403-408.
[40] SHAN C, ZHANG D, MA D N, et al. Osteocalcin ameliorates cognitive dysfunctions in a mouse model of Alzheimer’s disease by reducing amyloid β burden and upregulating glycolysis in neuroglia[J]. Cell Death Discov, 2023, 9(1): 46.